Incretin manipulation in diabetes management
| Autor: | Joseph M Pappachan, AV Raveendran, Rajagopalan Sriraman |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
endocrine system
endocrine system diseases business.industry Endocrinology Diabetes and Metabolism digestive oral and skin physiology Gastric motility Type 2 Diabetes Mellitus Incretin nutritional and metabolic diseases Hypoglycemia medicine.disease Bioinformatics Editorial Tolerability Diabetes management Diabetes mellitus Internal Medicine medicine Pancreatitis business hormones hormone substitutes and hormone antagonists |
| Zdroj: | World journal of diabetes. 6(6) |
| ISSN: | 1948-9358 |
| Popis: | Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus (T2DM) in the 21(st) century. Glucagon-like peptide-1 (GLP-1) suppresses appetite and gastric motility, and has trophic effects on pancreas, cardio-protective and renal effects. GLP-1 analogues and dipeptidyl peptidase-4 inhibitors form the incretin-based therapies. Significant reduction of hemoglobin A1c when used as monotherapy and in combination regimens, favorable effects on body weight, and low risk of hypoglycemia are their unique therapeutic benefits. Their safety and tolerability are comparable to other anti-diabetic medications. Concern about elevated risk of pancreatitis has been discarded by two recent meta-analyses. This article discusses the therapeutic manipulation of incretin system for the management of T2DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|